Detection of HIV antibodies in saliva as a tool for epidemiological studies. 1992

R van den Akker, and J A van den Hoek, and W M van den Akker, and H Kooy, and E Vijge, and G Roosendaal, and R A Coutinho, and A M van Loon
Laboratory of Virology, National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.

OBJECTIVE To evaluate the use of saliva specimens for the detection of HIV antibodies among high-risk groups in epidemiological studies. METHODS Testing of saliva specimens collected by different methods from individuals with known HIV status. The most reliable method was examined for its usefulness in a field study among a high-risk group. METHODS Saliva samples were obtained either by using a cotton-wool roll ('Salivette') or as 'whole saliva'. HIV antibodies were determined using commercial enzyme-linked immunosorbent assays (ELISA). Confirmation was performed using a line immunoassay or an immunoblot assay. RESULTS In 'Salivette' samples, HIV antibodies were detected by ELISA in seven out of 22 seropositive individuals. In contrast, testing of 'whole saliva' samples from 79 HIV-seropositive and 115 HIV-seronegative individuals resulted in a 100% correlation with HIV serum status. The positive reaction of 20 'whole saliva' specimens was confirmed in a line immunoassay, whereas in an immunoblot assay only seven specimens were positive, one negative, and 12 indeterminate. In an HIV prevalence study among drug users, 395 'whole saliva' samples were tested in two different ELISA. Both assays showed complete agreement in detecting 58 positive and 337 negative samples. All positive samples were confirmed by the line immunoassay. CONCLUSIONS Our study demonstrates that 'whole saliva' specimens are a good alternative to blood samples in epidemiological studies of HIV prevalence in high-risk groups.

UI MeSH Term Description Entries
D008297 Male Males
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D004812 Epidemiologic Methods Research techniques that focus on study designs and data gathering methods in human and animal populations. Epidemiologic Method,Epidemiological Methods,Methods, Epidemiologic,Epidemiological Method,Method, Epidemiologic,Method, Epidemiological,Methods, Epidemiological
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012463 Saliva The clear, viscous fluid secreted by the SALIVARY GLANDS and mucous glands of the mouth. It contains MUCINS, water, organic salts, and ptylin. Salivas
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences

Related Publications

R van den Akker, and J A van den Hoek, and W M van den Akker, and H Kooy, and E Vijge, and G Roosendaal, and R A Coutinho, and A M van Loon
January 1984, Developments in biological standardization,
R van den Akker, and J A van den Hoek, and W M van den Akker, and H Kooy, and E Vijge, and G Roosendaal, and R A Coutinho, and A M van Loon
January 1999, The National medical journal of India,
R van den Akker, and J A van den Hoek, and W M van den Akker, and H Kooy, and E Vijge, and G Roosendaal, and R A Coutinho, and A M van Loon
April 1993, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology,
R van den Akker, and J A van den Hoek, and W M van den Akker, and H Kooy, and E Vijge, and G Roosendaal, and R A Coutinho, and A M van Loon
September 1995, Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne,
R van den Akker, and J A van den Hoek, and W M van den Akker, and H Kooy, and E Vijge, and G Roosendaal, and R A Coutinho, and A M van Loon
October 1993, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
R van den Akker, and J A van den Hoek, and W M van den Akker, and H Kooy, and E Vijge, and G Roosendaal, and R A Coutinho, and A M van Loon
April 1995, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
R van den Akker, and J A van den Hoek, and W M van den Akker, and H Kooy, and E Vijge, and G Roosendaal, and R A Coutinho, and A M van Loon
January 1995, Indian journal of dental research : official publication of Indian Society for Dental Research,
R van den Akker, and J A van den Hoek, and W M van den Akker, and H Kooy, and E Vijge, and G Roosendaal, and R A Coutinho, and A M van Loon
April 1994, Presse medicale (Paris, France : 1983),
R van den Akker, and J A van den Hoek, and W M van den Akker, and H Kooy, and E Vijge, and G Roosendaal, and R A Coutinho, and A M van Loon
September 1993, Nihon rinsho. Japanese journal of clinical medicine,
R van den Akker, and J A van den Hoek, and W M van den Akker, and H Kooy, and E Vijge, and G Roosendaal, and R A Coutinho, and A M van Loon
April 1997, The Journal of the Association of Physicians of India,
Copied contents to your clipboard!